Market Overview

CytRx Reports Positive Results from Global Phase 2b Clinical Trial with Aldoxorubicin in Advanced Soft Tissue Sarcomas


(NASDAQ: CYTR) today reported positive
results from additional statistical analyses that further support the
previously announced highly positive top-line efficacy results from a
multicenter, randomized, open-label global Phase 2b clinical trial
investigating the efficacy and safety of aldoxorubicin compared with
doxorubicin as first-line therapy in subjects with metastatic, locally
advanced or unresectable soft tissue sarcomas (STS).

See full press release

Posted-In: News Guidance FDA Management Global


Related Articles (CYTR)

View Comments and Join the Discussion!

Partner Center